SCHEMBL7128124

SCHEMBL7128124

Clc1ccccc1SCCCN1CCN(C2=COC(C3=CC=CCC3)=CO2)CC1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
GRM2 Q14416 1/20 0.34
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
DRD2 P14416 4/20 0.31
DRD3 P35462 3/20 0.31
HTR1A P08908 3/20 0.31
DRD1 P21728 2/20 0.31
DRD5 P21918 2/20 0.31
HTR2A P28223 2/20 0.31
MAPT P10636 1/20 0.31
HTR7 P34969 1/20 0.31
HTR6 P50406 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128484 0.97 KDM4E (0.35) KDM4ELMNACYP1A2CYP2D6GRM2
SCHEMBL7120226 0.94 KDM4E (0.33) KDM4ELMNAADRA1AADRA1BDRD2
SCHEMBL7124367 0.93 GRM2 (0.40) KDM4ELMNACYP1A2CYP2D6GRM2
SCHEMBL7124383 0.90 DRD2 (0.34) KDM4ELMNAADRA1AADRA1BDRD2
SCHEMBL7117421 0.89 CYP1A2 (0.48) CYP1A2CYP2D6ADRA1BDRD2DRD3
SCHEMBL7128483 0.89 DRD2 (0.35) GRM2DRD2DRD3HTR1ADRD1
SCHEMBL7124127 0.88 HTR1A (0.32) KDM4EDRD2DRD3HTR1ADRD1
SCHEMBL7120272 0.88 DRD2 (0.37) CYP1A2CYP2D6GRM2ADRA1BDRD2
SCHEMBL7120263 0.87 KDM4E (0.34) KDM4ELMNAADRA1AADRA1BDRD2
SCHEMBL7127254 0.87 HTR7 (0.36) GRM2DRD2DRD3HTR2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US claimed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP claimed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO claimed
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US disclosed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP disclosed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use CRBN, CDR2, DRD3 KDM4E 2331/4885LMNA 2521/4885CYP1A2 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.